You are here: Industry Insights > PD-L1

News List

Imfinzi Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
February 10, 2021
The KESTREL Phase III trial for AstraZeneca’s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care ...
China has highest PD-1/PD-L1 combination immuno-oncology therapies clinical trials growth: GlobalData expresspharma
December 01, 2020
Between 2017 and 2019, the number of clinical trials initiated for PD-1/PD-L1 targeted combination therapies increased substantially, which continued in 2020, albeit with a significantly slower rate possibly due to the global COVID-19 pandemic.
FDA Accepts for Priority Review Libtayo for Advanced Non-small Cell Lung Cancer americanpharmaceuticalreview
November 09, 2020
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo® (cemiplimab-rwlc) to treat patients with ...
First HBV patient dosed in phase IIa clinical trial of ASC22 pharmaceutical-business-review
August 19, 2020
Ascletis Pharma announces the dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody.
China-based Biotech Laekna Acquires Global Rights to Develop and Commercialize anti-PD-L1 Antibody oncozine
March 30, 2020
Laekna will receive exclusive global rights to FAZ053, an investigational anti-PD-L1 antibody being developed by Novartis for the treatment of patients with advanced forms of cancer.
AlloHSCT Feasible After PD-1, PD-L1 mAb in Hodgkin Lymphoma drugs
December 25, 2019
Allogeneic hematopoietic stem cell transplantation (alloHSCT) performed after programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAB) treatment seems feasible for patients with classical Hodgkin lymphoma with ...
FDA Grants Accelerated Approval to enfortumab vedotin-ejfv americanpharmaceuticalreview
December 24, 2019
The Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (PADCEV, Astellas Pharma) for adult patients with locally advanced or ...
AZ' Imfinzi to be funded for NHS use via CDF pharmatimes
April 02, 2019
The National Institute for Health and Care Excellence (NICE) has recommended funding for use of AstraZeneca’s Imfinzi (durvalumab) on the NHS via the Cancer Drugs Fund.
China has Entered the Era of Tumor Immunotherapy: Updates on the R&D Progress of Anti-PD-(L)1 Antibodies PharmaSources/1℃
March 06, 2019
2018 was the first year of the tumor immunotherapy in China. The new era of tumor immunotherapy has begun in China with the marketing of anti-PD-(L)1 antibodies represented by Opdivo, Keytruda, and Tuoyi, etc. in China.
Merck's Keytruda looks to zoom past Opdivo with fast head and neck cancer review fiercepharma
February 12, 2019
Merck & Co.’s Keytruda is duking it out with Bristol-Myers Squibb’s Opdivo in the head and neck cancer marketplace, but Keytruda just took one step toward a green light that would give it a big edge.

Previous page 1 2 3 4 5 Next page